Abstract
Aims/Purpose: This project aimed to evaluate the efficacy of anti‐CD19 monoclonal antibody tafasitamab and experimental chemokine receptor blocker anti‐Hu CD199 and to study the impact of the microbiome on immunotherapy in an experimental immunocompetent murine model of primary intraocular lymphoma (PIOL).Methods: PIOL was induced in immunocompetent mice BALB/CaNn by intravitreal injection of syngeneic lymphoma A20‐CD19 cell suspension. To eliminate intestinal microflora, 50% of the mice were pre‐treated with broad‐spectrum antibiotics (metronidazole and ciprofloxacin). On days 3 and 7, mice were treated intravitreally either with tafasitamab (20 μg) or anti‐Hu CD199 (1 μg). Following the injection mice were monitored clinically 2 times per week. The experiment was terminated at the first signs of exophthalmos or on day 30. Eyes were collected post‐mortem and histologically processed.Results: In both treated groups the signs of PIOL were delayed in comparison to the control group. The untreated group started to show signs of PIOL on day 7. In the group treated with tafasitamab first signs of PIOL started to appear on days 10–14. In the group which received experimental anti‐Hu CD199, signs of PIOL first appeared on day 17. Development of exophthalmos was delayed as well, most significantly in the group treated with anti‐Hu CD199. So far, we did not observe statistically significant differences in PIOL behaviour and the effect of the treatment between the group with the intact microbiome and the group treated with antibiotics.Conclusions: Results of in vivo experiments confirm the efficacy of both tafasitamab and experimental anti‐Hu CD199 administered intravitreally in immunocompetent mice with PIOL. However, experimental chemokine receptor blocker anti‐Hu CD199 shows greater potential in the intravitreal treatment of PIOL.Financial support of this project: AZV MZ CR NU20‐03‐00253, SVV UK 260631.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
